Related Experiment Videos
COX-2-selective inhibitors in the treatment of arthritis
Thomas J Schnitzer1, Marc C Hochberg
1Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago, IL 60611, USA. tjs@nwu.edu
Abstract:
Therapy with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) has long been the cornerstone of pharmacologic management of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Many patients with OA or RA, however, are at increased risk of developing clinically significant adverse events associated with NSAID therapy, particularly upper gastrointestinal (GI) complications including symptomatic and complicated ulcers. The introduction of cyclooxygenase (COX)-2-selective inhibitors (coxibs) represents a major advance in the pharmacologic approach to the signs and symptoms of arthritis. In addition to the first two members of this class, celecoxib and rofecoxib, other coxibs have been introduced or are in development (valdecoxib, etoricoxib). In numerous clinical trials, coxibs have been shown to be as effective as nonselective NSAIDs in relieving pain and inflammation associated with OA and RA, and notably, with a significantly lower risk of NSAID-type adverse events. The use of coxibs to treat OA and RA is recommended as first-line therapy when symptoms of pain and inflammation are present in patients vulnerable to potential NSAID-associated GI toxicity.
Insights
Cyclooxygenase (COX)-2-selective inhibitors (coxibs) offer effective arthritis pain relief with fewer gastrointestinal risks than traditional nonsteroidal anti-inflammatory drugs (NSAIDs). They are recommended for patients with osteoarthritis (OA) and rheumatoid arthritis (RA) at risk for NSAID complications.
Area of Science:
- Pharmacology
- Rheumatology
- Gastroenterology
Background:
- Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are standard for osteoarthritis (OA) and rheumatoid arthritis (RA) but carry significant gastrointestinal (GI) risks.
- Patients with OA and RA are susceptible to serious adverse events, including upper GI complications like ulcers, from NSAID therapy.
Purpose of the Study:
- To evaluate cyclooxygenase (COX)-2-selective inhibitors (coxibs) as an alternative to nonselective NSAIDs for arthritis management.
- To assess the efficacy and safety profile of coxibs compared to traditional NSAIDs in treating OA and RA.
Main Methods:
- Review of numerous clinical trials comparing coxibs with nonselective NSAIDs.
- Assessment of pain relief, inflammation reduction, and incidence of NSAID-type adverse events.
Main Results:
- Coxibs demonstrate comparable efficacy to nonselective NSAIDs in managing OA and RA symptoms.
- Coxibs are associated with a significantly reduced risk of NSAID-related adverse gastrointestinal events.
Conclusions:
- Coxibs represent a significant advancement in arthritis pharmacotherapy.
- Recommended as first-line treatment for OA and RA patients experiencing pain and inflammation, especially those at risk for NSAID-induced GI toxicity.